Purpose Patients with advanced non-small cell lung cancer (NSCLC) harboring a sensitive
epidermal growth factor receptor (EGFR) mutation have been shown to exhibit a marked …

Objectives Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (ie, EGFR-
TKIs) improve the survival of lung cancer patients harboring EGFR mutations. Despite the …

Purpose This study was undertaken to investigate the efficacy and the feasibility of gefitinib
for chemotherapy-naïve patients with advanced non–small-cell lung cancer (NSCLC) …

Purpose Whether bevacizumab enhances the effect of the epidermal growth factor receptor
(EGFR) inhibitor gefitinib on EGFR mutant non–small cell lung cancers (NSCLCs) remains …

Purpose To determine whether the addition of pemetrexed to gefitinib (P+ G) provides
clinical benefit, compared with gefitinib monotherapy, in patients with advanced …

Objective Epidermal growth factor receptor tyrosine kinase inhibitors are effective as first-line
therapy for advanced non-small cell lung cancer patients harboring epidermal growth factor …

Introduction Although standard schedule of gefitinib was the administration of 250 mg tablet
every day, many patients need dose reduction because of toxicities. However, the efficacy of …

TPS8131 Background: Based on the previous phase III studies including our NEJ002 study
comparing G with platinum doublet, G alone has been accepted as the standard first-line …

9001 Background: Standard first-line therapy for EGFR mutant advanced non-small cell lung
cancer (NSCLC) is an EGFR-directed oral TKI. We evaluated whether adding pemetrexed …

Purpose This multicenter phase II study was undertaken to investigate the efficacy and
feasibility of gefitinib for patients with advanced non–small-cell lung cancer (NSCLC) …